Abstract: Objective To evaluate the clinical efficacy and safety of non-ablative 1540 nm erbium-glass fractional laser on treating facial post-acne lesions, including atrophic scars, enlarged pores, post-acne erythema and post-inflammatory hyperpigmentation (PIH). Methods A non-ablative 1540 nm erbium-glass fractional laser was used to treat 28 patients. All patients were treated for 3-9 times with an interval of 4-week. The efficacy was assessed by A quartile grading scale, VISIA complexion analysis system and CK skin property 1 month after treatment. Results The efficacy rate of non-ablative 1540 nm erbium-glass fractional laser was 14.29% for post-acne scars, 25% for enlarged pores, 34.76% for post-acne erythema and 18.18% for PIH. Compared to pre-therapy, there was significant difference in pores, erythema and purple mass, and there was positive correlation between efficacy and treatment frequencies (P0.05). No severe adverse effect was observed. Conclusion Non-ablative 1540 nm erbium-glass fractional laser was safe and effective in treating post-acne skin lesions, especially for post-acne erythema and enlarged pores.

Key words: Erbium glass, Fractional laser, Post-acne lesions